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reverse remodeling drug because the final dose of carvedilol was
25% higher in this treatment arm. This would be expected from
previous large-scale beta-blocker trials. Any additional agent on
top of what is already working may yield a smaller incremental
effect as the investigators also demonstrated in the perindopril-
initiated arm.
What this “humble” study confirms are that beta-blockers are
important in patients with NYHA functional class II or above, that
diligence and patience must be used to up-titrate to the highest
dose tolerated, and that we should not withhold use of beta-
blockade even if a patient feels better without it. The impact of the
study is not which agent to initiate first, but that both must be used
without delay.
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Beta-Blocker Treatment Before
Angiotensin-Converting Enzyme Inhibitor
Therapy in Newly Diagnosed Heart Failure
We read with great interest the study by Sliwa et al. (1) recently
published in the Journal. In their report they observed that,
compared to the commonly recommended order of starting ther-
apy for newly diagnosed heart failure with an angiotensin-
converting enzyme inhibitor (ACEI) followed by a beta-blocker,
the opposite order of starting with the beta-blocker carvedilol
followed by the ACEI perindopril had a superior effect on New
York Heart Association (NYHA) functional class, left ventricular
ejection fraction (LVEF), plasma N-terminal pro-brain natriuretic
peptide concentration, and LV volumes. We believe that this is a
very important study and the investigators are to be congratulated
for their achievement. In his accompanying editorial (2), Dr. Leier
points out that a large multicenter morbidity/mortality trial would
have to be performed to verify the results obtained by Sliwa et al.
In response to this we would like to inform readers of JACC
that, based on a hypothesis similar to the one by Sliwa et al., we
started planning such a morbidity/mortality trial more than four
years ago. The rationale and design of this trial, the Cardiac
Insufficiency Bisoprolol Study (CIBIS)-III, has been published (3),
and the study is now concluded. In 18 European countries, as well
as in Tunisia and Australia, 1,013 patients with NYHA functional
class II to III heart failure have been included.
The CIBIS-III trial is designed to provide evidence for the best
order of initiating therapy. The end point rate is as expected,
ensuring an adequate statistical power to show noninferiority or
superiority for bisoprolol-first, should that be the case. If superi-
ority for either treatment regimen is shown we will know if we
generally should start heart failure therapy with an ACEI or a
beta-blocker. If the trial shows noninferiority for bisoprolol-first
versus enalapril-first, there is evidence supporting a free choice
with regard to the first therapy, based on individual judgment in
each patient. A result showing that bisoprolol-first is superior to
enalapril-first will challenge the paradigm of testing compounds
for the treatment of heart failure against a background of ACEI
therapy.
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Treatment Order in Managing
Systolic Ventricular Dysfunction
Dr. Leier (1) has made a useful and provocative commentary on
the work of Sliwa et al. (2). Clearly Dr. Leier is impressed by the
principle of testing order effects in the management of systolic left
ventricular (LV) dysfunction. This is a very wise and long overdue
assessment although not performed in a double-blinded random-
ized crossover design that would be expected to characterize an
order effect. It would be equally wise to retain balance in estimating
the impact or generalizability of this work.
First, it is often forgotten that all modern studies in systolic
failure involve structured addition of therapy to established treat-
ments. Although we often focus on the added therapy we tend to
ignore the baseline, which is constantly changing and makes
proving efficacy of a new addition consequently more challenging.
For example, all patients in the angiotensin-converting enzyme
(ACE) inhibitor, ino-dilator, or vasodilator and digoxin systolic
failure trials of the 1980s and 1990s were subjected to loop diuretic
therapy, which has a powerful impact in stimulating the circulating
and tissue-based (renin-angiotensin-aldosterone system). The
well-characterized and accepted adverse effects of the changes
caused by these treatments are balanced in the individual patient by
the beneficial effect on fluid volume and loading. Although
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beta-blockade will suppress renin, it does so inefficiently compared
to ACE inhibition. To presume that beta-blocker addition follow-
ing an ACE inhibitor is the same as the addition of an ACE
inhibitor after a beta-blocker is simply wrong. To suggest that
beta-blockade should be given first and an ACE inhibitor not at all
is equally wrong. To presume that an ACE inhibitor after a
beta-blocker would be ineffectual or of little value from the limited
work of Sliwa and colleagues is at best an overstatement.
Second, the patients in this study are likely to be Africans (a
critical missing statement that avoided detection in the review
process?). This patient group, in addition to being rarely studied,
is at least well known to show reduced response to renin system
blockade. Furthermore, the subjects are unusual in that they are all
suggested to have idiopathic dilated cardiomyopathy. This would
be rare in a Westernized cohort relevant to the U.S. or Europe.
We believe Dr. Leier should not fear for the efficacy of ACE
inhibitor therapy in systolic LV dysfunction, although he is very
correct to draw attention to the significance of order effects in
therapeutics. These have been well recognized in cardiovascular
pharmacology for over a century. A more temperate interpretation
of Silwa’s study results would be that beta-blockade should be
introduced in patients with systolic heart failure as soon as possible
after diagnosis, and certainly without a six-month delay. Physicians
might reasonably initiate a beta-blocker prior to an ACE inhibitor
in those patients with euvolemic “dry” heart failure, and an ACE
inhibitor first in those with persisting congestion, with plans to add
a beta-blocker as soon as the congestion has resolved.
*Robert J. MacFadyen, MD, PhD, FRCP
Russell Davis, MD, MRCP
*University Department of Medicine
City Hospital
Dudley Road
Birmingham B18 7QH
United Kingdom
E-mail: robert.macfadyen@swbh.nhs.uk
doi:10.1016/j.jacc.2005.04.012
REFERENCES
1. Leier CV. Dismantling mandates in the treatment of heart failure. J Am
Coll Cardiol 2004;44:1831–3.
2. Silwa K, Norton GR, Kone N, et al. Impact of initiating carvedilol
before angiotensin-converting enzyme inhibitor therapy on cardiac
function in newly diagnosed heart failure. J Am Coll Cardiol
2004;44:1825–30.
REPLY
We appreciate the interest in our recently published study (1). Dr.
Law raises several concerns, some of which we find puzzling.
Baragwanath is the only hospital serving a population of some
three million; with a bed capacity of 3,300, it is the largest hospital
in the Southern Hemisphere and has a cardiac clinic that sees some
25,000 patients annually. In this context, it is not difficult to
understand how 100 or more new patients with idiopathic dilated
cardiomyopathy might be recruited each year. The majority of
these patients receive workup and therapy as outpatients. For us,
and surely for many other busy units, these patients represent “real
clinical practice.” Dr. Law questions the six-month delay in
starting carvedilol in the “ACE-I first” group. We cannot under-
stand his concern as this in essence was the design of the study to
answer the issue at hand. Our study and the CIBIS-III trial have
chosen monotherapy with an ACE inhibitor versus a beta-blocker
for six months followed by combination of both agents to study the
impact of the individual and subsequent combination effect of each
drug on left ventricular (LV) function. There is no direct scientific
evidence of the exact duration when an impact on remodeling of
the left ventricle can be expected. However, it will be several
months rather than a few weeks.
The question as to the mechanism of benefit is speculative but
does not detract from the important finding that the beta-blocker–
first strategy was superior. The notion that beta-blockade may be
harmful when initiated in patients with advanced heart failure was
clearly dispelled by the results of the COPERNICUS study (2),
which showed carvedilol to be beneficial even in class IV heart
failure.
We fully agree with the sentiments of Dr. MacFadyen et al.
regarding the pharmacologic importance of the sequence in which
drug therapy is initiated, especially in a condition such as heart
failure, where multidrug therapy is the rule and where optimal
doses may be severely handicapped by hypotension. Both ethnicity
and the response to drug therapy are important issues, and it is
notable that the majority of our patients were black Africans who
have been shown to respond differently to ACE inhibitors in the
setting of hypertension and possibly also in heart failure (3). That
is why we believe it is important that further investigation in larger
studies, using different ethnic groups and other etiologies of heart
failure, such as ischemic cardiomyopathy, be undertaken, first, to
confirm our results and, second, to determine their generalizability.
The efforts of the CIBIS-III investigators (4) and their comments
on our findings are appreciated and we eagerly await publication of
their results.
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